Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 15
Treatment-assignment count: 0
Stratification count: 0
Manual Review Required
HER2 / ERBB2 expression
NSCLC · Therapy Not Normalized
HER2 / ERBB2 expression is flagged as manual review required because public trials show inclusion required evidence in 21 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 4
Common snippets: EGFR exon 19 deletion | KRAS G12C | BRAF V600E
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Manual Review Required
CDx maturity score: 2/5
Confidence: Low
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT00063154 | https://clinicaltrials.gov/study/NCT07291037 | https://clinicaltrials.gov/study/NCT05653752 | https://clinicaltrials.gov/study/NCT02965885 | https://clinicaltrials.gov/study/NCT05364073 | https://clinicaltrials.gov/study/NCT06329895 | https://clinicaltrials.gov/study/NCT04576208 | https://clinicaltrials.gov/study/NCT06253871 | https://clinicaltrials.gov/study/NCT03808662 | https://clinicaltrials.gov/study/NCT06563999 | https://clinicaltrials.gov/study/NCT06706076 | https://clinicaltrials.gov/study/NCT00548093 | https://clinicaltrials.gov/study/NCT03066206 | https://clinicaltrials.gov/study/NCT06221475 | https://clinicaltrials.gov/study/NCT04129502 | https://clinicaltrials.gov/study/NCT02183883 | https://clinicaltrials.gov/study/NCT06081907 | https://clinicaltrials.gov/study/NCT01730118 | https://clinicaltrials.gov/study/NCT05546268 | https://clinicaltrials.gov/study/NCT04818333 | https://clinicaltrials.gov/study/NCT00073008